Published in Nature on May 12, 2011
The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88
Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (2011) 11.12
Interpreting cancer genomes using systematic host network perturbations by tumour virus proteins. Nature (2012) 4.35
IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature (2012) 4.04
Leukaemogenesis induced by an activating β-catenin mutation in osteoblasts. Nature (2014) 2.70
Loss of the tumor suppressor BAP1 causes myeloid transformation. Science (2012) 2.69
Oncogenic and tumor suppressor functions of Notch in cancer: it's NOTCH what you think. J Exp Med (2011) 2.40
IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development. Cancer Cell (2011) 2.05
TET family proteins and their role in stem cell differentiation and transformation. Cell Stem Cell (2011) 1.87
The molecular pathogenesis of head and neck squamous cell carcinoma. J Clin Invest (2012) 1.86
Complementary genomic screens identify SERCA as a therapeutic target in NOTCH1 mutated cancer. Cancer Cell (2013) 1.86
Notch-dependent repression of miR-155 in the bone marrow niche regulates hematopoiesis in an NF-κB-dependent manner. Cell Stem Cell (2014) 1.81
Notch-RBP-J signaling regulates the transcription factor IRF8 to promote inflammatory macrophage polarization. Nat Immunol (2012) 1.81
Conformational locking upon cooperative assembly of notch transcription complexes. Structure (2012) 1.79
Notch pathway activation targets AML-initiating cell homeostasis and differentiation. J Exp Med (2013) 1.71
Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo. J Exp Med (2013) 1.71
From fly wings to targeted cancer therapies: a centennial for notch signaling. Cancer Cell (2014) 1.70
Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma. J Exp Med (2012) 1.66
The great migration of bone marrow-derived stem cells toward the ischemic brain: therapeutic implications for stroke and other neurological disorders. Prog Neurobiol (2011) 1.61
Notch activation inhibits AML growth and survival: a potential therapeutic approach. J Exp Med (2013) 1.54
The double-edged sword of Notch signaling in cancer. Semin Cell Dev Biol (2012) 1.53
Ikaros inhibits megakaryopoiesis through functional interaction with GATA-1 and NOTCH signaling. Blood (2013) 1.52
Cancer stem cells in lung cancer: Evidence and controversies. Respirology (2013) 1.46
T-cell factor 1 is a gatekeeper for T-cell specification in response to Notch signaling. Proc Natl Acad Sci U S A (2011) 1.41
Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited. J Clin Oncol (2012) 1.40
The PIAS-like Coactivator Zmiz1 Is a Direct and Selective Cofactor of Notch1 in T Cell Development and Leukemia. Immunity (2015) 1.39
Notch signaling: switching an oncogene to a tumor suppressor. Blood (2014) 1.32
Satb1 regulates the self-renewal of hematopoietic stem cells by promoting quiescence and repressing differentiation commitment. Nat Immunol (2013) 1.28
Cutaneous papillomavirus E6 oncoproteins associate with MAML1 to repress transactivation and NOTCH signaling. Oncogene (2012) 1.27
Blockade of individual Notch ligands and receptors controls graft-versus-host disease. J Clin Invest (2013) 1.27
Developmental pathways in colon cancer: crosstalk between WNT, BMP, Hedgehog and Notch. Cell Cycle (2012) 1.26
Gamma secretase inhibitors of Notch signaling. Onco Targets Ther (2013) 1.21
Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells. J Clin Invest (2013) 1.20
Self-renewal related signaling in myeloid leukemia stem cells. Int J Hematol (2011) 1.17
Activation of the NOTCH pathway in head and neck cancer. Cancer Res (2013) 1.15
In vivo mapping of notch pathway activity in normal and stress hematopoiesis. Cell Stem Cell (2013) 1.14
T cell development requires constraint of the myeloid regulator C/EBP-α by the Notch target and transcriptional repressor Hes1. Nat Immunol (2013) 1.07
NOTCH1 activation clinically antagonizes the unfavorable effect of PTEN inactivation in BFM-treated children with precursor T-cell acute lymphoblastic leukemia. Haematologica (2013) 1.06
Transcriptome profiling of the cancer, adjacent non-tumor and distant normal tissues from a colorectal cancer patient by deep sequencing. PLoS One (2012) 1.04
Deletion of the NF-κB subunit p65/RelA in the hematopoietic compartment leads to defects in hematopoietic stem cell function. Blood (2013) 1.02
miR-9 is an essential oncogenic microRNA specifically overexpressed in mixed lineage leukemia-rearranged leukemia. Proc Natl Acad Sci U S A (2013) 1.01
Specific Notch receptor-ligand interactions control human TCR-αβ/γδ development by inducing differential Notch signal strength. J Exp Med (2013) 1.00
Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents. Nat Commun (2016) 0.99
Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides. Blood (2015) 0.99
Notch3 functions as a tumor suppressor by controlling cellular senescence. Cancer Res (2013) 0.98
GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia. Blood (2013) 0.96
T cell-specific notch inhibition blocks graft-versus-host disease by inducing a hyporesponsive program in alloreactive CD4+ and CD8+ T cells. J Immunol (2013) 0.96
Notch signaling in pancreatic cancer: oncogene or tumor suppressor? Trends Mol Med (2013) 0.95
NOTCH pathway inactivation promotes bladder cancer progression. J Clin Invest (2015) 0.95
Divergent effects of supraphysiologic Notch signals on leukemia stem cells and hematopoietic stem cells. Blood (2012) 0.95
Molecular consequences of amyloid precursor protein and presenilin mutations causing autosomal-dominant Alzheimer's disease. Alzheimers Res Ther (2012) 0.95
Dll4-Notch signaling in Flt3-independent dendritic cell development and autoimmunity in mice. J Exp Med (2012) 0.95
An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms. Haematologica (2015) 0.94
Nontranscriptional role of Hif-1α in activation of γ-secretase and notch signaling in breast cancer. Cell Rep (2014) 0.94
New somatic mutations and WNK1-B4GALNT3 gene fusion in papillary thyroid carcinoma. Oncotarget (2015) 0.94
Notch-EGFR/HER2 Bidirectional Crosstalk in Breast Cancer. Front Oncol (2014) 0.94
Targeting cell cycle regulators in hematologic malignancies. Front Cell Dev Biol (2015) 0.92
GATA-1 utilizes Ikaros and polycomb repressive complex 2 to suppress Hes1 and to promote erythropoiesis. Mol Cell Biol (2012) 0.91
A genome-scale in vivo loss-of-function screen identifies Phf6 as a lineage-specific regulator of leukemia cell growth. Genes Dev (2015) 0.91
The emerging roles of Notch signaling in leukemia and stem cells. Biomark Res (2013) 0.90
Early T-cell progenitors are the major granulocyte precursors in the adult mouse thymus. Blood (2012) 0.90
Epigenetic inactivation of Notch-Hes pathway in human B-cell acute lymphoblastic leukemia. PLoS One (2013) 0.89
Pituitary gland development and disease: from stem cell to hormone production. Curr Top Dev Biol (2013) 0.88
Acute loss of TET function results in aggressive myeloid cancer in mice. Nat Commun (2015) 0.88
New Approaches to Target T-ALL. Front Oncol (2014) 0.88
NOTCH1 signaling promotes human T-cell acute lymphoblastic leukemia initiating cell regeneration in supportive niches. PLoS One (2012) 0.87
Prioritizing cancer-related genes with aberrant methylation based on a weighted protein-protein interaction network. BMC Syst Biol (2011) 0.87
TiF1-gamma plays an essential role in murine hematopoiesis and regulates transcriptional elongation of erythroid genes. Dev Biol (2012) 0.87
Hes1 suppresses acute myeloid leukemia development through FLT3 repression. Leukemia (2014) 0.87
Targeting self-renewal pathways in myeloid malignancies. Cell Commun Signal (2013) 0.87
Ubiquitinations in the notch signaling pathway. Int J Mol Sci (2013) 0.86
Notch signaling contributes to lung cancer clonogenic capacity in vitro but may be circumvented in tumorigenesis in vivo. Mol Cancer Res (2011) 0.86
HES1, a target of Notch signaling, is elevated in canine osteosarcoma, but reduced in the most aggressive tumors. BMC Vet Res (2013) 0.85
Anti-tumor effects of the Notch pathway in gastrointestinal stromal tumors. Carcinogenesis (2012) 0.85
Proteinase-Activated Receptor 1 (PAR1) regulates leukemic stem cell functions. PLoS One (2014) 0.83
Notch signaling regulates T cell accumulation and function in the central nervous system during experimental autoimmune encephalomyelitis. J Immunol (2013) 0.83
Growth factor independent-1 maintains Notch1-dependent transcriptional programming of lymphoid precursors. PLoS Genet (2013) 0.83
Functional genomics identifies negative regulatory nodes controlling phagocyte oxidative burst. Nat Commun (2015) 0.82
Hesperetin activates the Notch1 signaling cascade, causes apoptosis, and induces cellular differentiation in anaplastic thyroid cancer. Ann Surg Oncol (2014) 0.82
Oral cavity and oropharyngeal squamous cell carcinoma genomics. Otolaryngol Clin North Am (2013) 0.82
Noncanonical Notch signaling modulates cytokine responses of dendritic cells to inflammatory stimuli. J Immunol (2012) 0.82
Mutually exclusive mutations in NOTCH1 and PIK3CA associated with clinical prognosis and chemotherapy responses of esophageal squamous cell carcinoma in China. Oncotarget (2016) 0.82
Notch1 is not required for acinar-to-ductal metaplasia in a model of Kras-induced pancreatic ductal adenocarcinoma. PLoS One (2012) 0.81
Pleiotropic roles of Notch signaling in normal, malignant, and developmental hematopoiesis in the human. EMBO Rep (2014) 0.81
Alternative lengthening of telomeres: recurrent cytogenetic aberrations and chromosome stability under extreme telomere dysfunction. Neoplasia (2013) 0.81
Multivalent Forms of the Notch Ligand DLL-1 Enhance Antitumor T-cell Immunity in Lung Cancer and Improve Efficacy of EGFR-Targeted Therapy. Cancer Res (2015) 0.81
Role of Notch signaling in regulating innate immunity and inflammation in health and disease. Protein Cell (2016) 0.81
Janus kinase 3: the controller and the controlled. Acta Biochim Biophys Sin (Shanghai) (2011) 0.81
Cleaved NOTCH1 Expression Pattern in Head and Neck Squamous Cell Carcinoma Is Associated with NOTCH1 Mutation, HPV Status, and High-Risk Features. Cancer Prev Res (Phila) (2015) 0.81
The NOTCH signaling pathway in normal and malignant blood cell production. J Cell Commun Signal (2015) 0.80
Identification of renin progenitors in the mouse bone marrow that give rise to B-cell leukaemia. Nat Commun (2014) 0.80
Notch signaling in the malignant bone marrow microenvironment: implications for a niche-based model of oncogenesis. Ann N Y Acad Sci (2014) 0.80
Moving towards personalised therapy in head and neck squamous cell carcinoma through analysis of next generation sequencing data. Eur J Cancer (2016) 0.79
Contrasting roles for C/EBPα and Notch in irradiation-induced multipotent hematopoietic progenitor cell defects. Stem Cells (2015) 0.79
Prostate tumor OVerexpressed-1 (PTOV1) down-regulates HES1 and HEY1 notch targets genes and promotes prostate cancer progression. Mol Cancer (2014) 0.79
Cancer: The flipside of Notch. Nature (2011) 0.79
Genomic analyses reveal FAM84B and the NOTCH pathway are associated with the progression of esophageal squamous cell carcinoma. Gigascience (2016) 0.79
Notch signaling in acute promyelocytic leukemia. Leukemia (2013) 0.79
Structural analysis of Notch-regulating Rumi reveals basis for pathogenic mutations. Nat Chem Biol (2016) 0.78
Notch-modifying xylosyltransferase structures support an SNi-like retaining mechanism. Nat Chem Biol (2015) 0.78
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet (2003) 53.59
Inducible gene targeting in mice. Science (1995) 21.22
Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature (2006) 11.90
High-efficiency deleter mice show that FLPe is an alternative to Cre-loxP. Nat Genet (2000) 11.80
Deficient T cell fate specification in mice with an induced inactivation of Notch1. Immunity (1999) 8.33
Functional analysis of secreted and transmembrane proteins critical to mouse development. Nat Genet (2001) 5.67
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia (2010) 4.09
Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia. Nat Rev Cancer (2006) 3.89
Notch2 is preferentially expressed in mature B cells and indispensable for marginal zone B lineage development. Immunity (2003) 3.73
Distinct hematopoietic stem cell subtypes are differentially regulated by TGF-beta1. Cell Stem Cell (2010) 3.69
Molecular pathogenesis of T-cell leukaemia and lymphoma. Nat Rev Immunol (2008) 3.57
Molecular genetics of T cell development. Annu Rev Immunol (2005) 3.26
Genome-wide lineage-specific transcriptional networks underscore Ikaros-dependent lymphoid priming in hematopoietic stem cells. Immunity (2009) 3.18
Defining brain wiring patterns and mechanisms through gene trapping in mice. Nature (2001) 3.07
Notch-deficient skin induces a lethal systemic B-lymphoproliferative disorder by secreting TSLP, a sentinel for epidermal integrity. PLoS Biol (2008) 2.98
Assessing the role of hematopoietic plasticity for endothelial and hepatocyte development by non-invasive lineage tracing. Development (2004) 2.88
Notch activation induces apoptosis in neural progenitor cells through a p53-dependent pathway. Dev Biol (2004) 2.59
JunB protects against myeloid malignancies by limiting hematopoietic stem cell proliferation and differentiation without affecting self-renewal. Cancer Cell (2009) 2.41
Crossing paths with Notch in the hyper-network. Curr Opin Cell Biol (2007) 2.20
Control of hematopoietic stem cell quiescence by the E3 ubiquitin ligase Fbw7. J Exp Med (2008) 2.19
Delayed, asynchronous, and reversible T-lineage specification induced by Notch/Delta signaling. Genes Dev (2005) 1.98
CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia. Nature (2009) 1.94
Atopic dermatitis-like disease and associated lethal myeloproliferative disorder arise from loss of Notch signaling in the murine skin. PLoS One (2010) 1.92
T-cell development made simple. Nat Rev Immunol (2004) 1.84
Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. Leukemia (2008) 1.82
Impaired embryonic haematopoiesis yet normal arterial development in the absence of the Notch ligand Jagged1. EMBO J (2008) 1.71
Notch signaling specifies megakaryocyte development from hematopoietic stem cells. Cell Stem Cell (2008) 1.58
An early decrease in Notch activation is required for human TCR-alphabeta lineage differentiation at the expense of TCR-gammadelta T cells. Blood (2008) 1.44
Notch signaling is required for proliferation but not for differentiation at a well-defined beta-selection checkpoint during human T-cell development. Blood (2008) 1.23
Nicastrin: gatekeeper of the gamma-secretase complex. Cell (2005) 1.05
Early T cell receptor beta gene expression is regulated by the pre-T cell receptor-CD3 complex. J Exp Med (1999) 1.04
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell (2010) 15.20
The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell (2010) 13.13
Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med (2012) 10.20
Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med (2011) 9.90
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med (2007) 8.18
IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature (2012) 7.95
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med (2006) 7.95
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell (2011) 7.37
Antibiotics in early life alter the murine colonic microbiome and adiposity. Nature (2012) 6.37
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood (2006) 5.95
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood (2009) 5.72
The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer (2012) 4.97
Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med (2011) 4.91
Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med (2006) 4.63
Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. J Biol Chem (2002) 4.52
Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays. Am J Hum Genet (2007) 4.52
Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms. Mol Cell (2008) 4.44
Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell (2012) 4.41
Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. J Clin Invest (2010) 4.22
The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J Exp Med (2007) 4.04
Role for Akt3/protein kinase Bgamma in attainment of normal brain size. Mol Cell Biol (2005) 4.00
Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med (2008) 3.98
Single cell behavior in metastatic primary mammary tumors correlated with gene expression patterns revealed by molecular profiling. Cancer Res (2002) 3.95
Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood (2006) 3.88
Requirement for cyclin D3 in lymphocyte development and T cell leukemias. Cancer Cell (2003) 3.86
Molecular pathogenesis of T-cell leukaemia and lymphoma. Nat Rev Immunol (2008) 3.57
Determinants of human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic T lymphocyte response. J Exp Med (2004) 3.48
The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood (2005) 3.47
Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell (2012) 3.39
Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet (2012) 3.33
High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood (2008) 3.30
Molecular genetics of T cell development. Annu Rev Immunol (2005) 3.26
Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell (2007) 3.23
Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. Eur Urol (2012) 3.20
EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell (2013) 3.13
A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet (2009) 3.10
Genetics of myeloid malignancies: pathogenetic and clinical implications. J Clin Oncol (2005) 2.94
Myc is a Notch1 transcriptional target and a requisite for Notch1-induced mammary tumorigenesis in mice. Proc Natl Acad Sci U S A (2006) 2.92
Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol (2012) 2.92
Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J Clin Oncol (2013) 2.90
Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat Med (2012) 2.86
Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell (2008) 2.80
Regulation of immunoglobulin light-chain recombination by the transcription factor IRF-4 and the attenuation of interleukin-7 signaling. Immunity (2008) 2.72
TET2 and TET3 regulate GlcNAcylation and H3K4 methylation through OGT and SET1/COMPASS. EMBO J (2013) 2.70
Loss of the tumor suppressor BAP1 causes myeloid transformation. Science (2012) 2.69
Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res (2010) 2.69
PHF6 mutations in T-cell acute lymphoblastic leukemia. Nat Genet (2010) 2.66
Early-stage epigenetic modification during somatic cell reprogramming by Parp1 and Tet2. Nature (2012) 2.64
DNA replication timing and long-range DNA interactions predict mutational landscapes of cancer genomes. Nat Biotechnol (2011) 2.62
JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation. Cancer Cell (2011) 2.56
Synergy and discounting of cooperation in social dilemmas. J Theor Biol (2005) 2.49
Stochastic tunnels in evolutionary dynamics. Genetics (2004) 2.42
ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell (2012) 2.42
Oncogenic and tumor suppressor functions of Notch in cancer: it's NOTCH what you think. J Exp Med (2011) 2.40
Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia. Nat Genet (2013) 2.38
Outbreak of variant influenza A(H3N2) virus in the United States. Clin Infect Dis (2013) 2.38
Hierarchical model of gene regulation by transforming growth factor beta. Proc Natl Acad Sci U S A (2003) 2.37
Evolution of resistance during clonal expansion. Genetics (2006) 2.36
Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia. Nat Med (2006) 2.35
Regulation of pluripotency and cellular reprogramming by the ubiquitin-proteasome system. Cell Stem Cell (2012) 2.35
Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci U S A (2009) 2.32
MicroRNA-16 and microRNA-424 regulate cell-autonomous angiogenic functions in endothelial cells via targeting vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1. Arterioscler Thromb Vasc Biol (2011) 2.31
miR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis. Cancer Cell (2011) 2.30
Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature (2012) 2.28
eIF4GI links nutrient sensing by mTOR to cell proliferation and inhibition of autophagy. J Cell Biol (2008) 2.26
The HIF signaling pathway in osteoblasts directly modulates erythropoiesis through the production of EPO. Cell (2012) 2.25
The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability. Cell (2013) 2.24
Control of hematopoietic stem cell quiescence by the E3 ubiquitin ligase Fbw7. J Exp Med (2008) 2.19
Progression of RAS-mutant leukemia during RAF inhibitor treatment. N Engl J Med (2012) 2.19
The Notch/Hes1 pathway sustains NF-κB activation through CYLD repression in T cell leukemia. Cancer Cell (2010) 2.09